Abstract 711TiP
Background
TAK-186 is a COnditional Bispecific Redirected Activation (COBRA) T-cell engager designed to bind to epidermal growth factor receptor (EGFR). Protease-mediated activation of the prodrug, primarily in the tumor microenviroment, generates an active dimer of EGFR-bound TAK-186 which engages CD3 T cells via the CD3ε binding domain. As the tumor microenvironment has increased protease activity vs healthy tissues, TAK-186 could potentially have an improved safety profile and therapeutic efficacy in solid tumors compared with other T-cell engagers that do not depend on conditional activation.
Trial design
This is a first-in-human, open-label, phase 1/2 study of TAK-186 (NCT04844073), with a planned enrollment of ∼123 patients (pts) with unresectable, locally advanced/metastatic EGFR-expressing solid tumors, including but not limited to non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell cancer (HNSCC). Eligibility criteria include age ≥18 yr, ECOG PS ≤1, and measurable disease per RECIST v1.1. Pts who received an immune checkpoint inhibitor (ICI) prior to enrollment must have ICI immune-related toxicity resolved to Grade ≤1 or baseline (prior to ICI). Key exclusion criteria include history of autoimmune disease, major surgery ≤8 wks or radiation therapy <2 wks before first dose of TAK-186, history of clinically significant cardiac or gastrointestinal disorders. The study will be conducted in two phases: a dose-escalation phase (sequential cohorts of escalating doses) followed by a cohort-expansion phase (advanced/metastatic EGFR-expressing NSCLC, CRC, HNSCC). Pts will be followed for survival after treatment discontinuation. The primary objective is characterization of safety, tolerability, and dose-limiting toxicities. Secondary objectives include characterization of pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity. Tumor evaluation will be done using RECIST 1.1 and modified RECIST 1.1. Safety data will be summarized by CTCAE v5.0. Cytokine release syndrome will be reported by ASTCT consensus grading. Recruitment is ongoing.
Clinical trial identification
NCT04844073.
Editorial acknowledgement
Under the direction of the authors, Sweta Rathore, PhD, (Caudex, Toronto, Canada), provided writing assistance, and Hannah Lederman, MPhil, (Caudex, New York, USA), provided editorial assistance. Medical writing and editorial services were funded by Takeda Development Center Americas, Inc.
Legal entity responsible for the study
Takeda Development Center Americas, Inc.
Funding
Takeda Development Center Americas, Inc.
Disclosure
A.J. Weickhardt: Financial Interests, Personal, Other, Honoraria: Eisai, Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Merck Sharp & Dohm; Financial Interests, Personal, Speaker, Consultant, Advisor: Astellas Pharma; Financial Interests, Personal, Other, Travel, accommodations, expenses: Astellas Pharma, Ipsen, Merck Sharp & Dohme; Financial Interests, Personal, Research Grant: Merck. S. Frentzas: Financial Interests, Personal, Advisory Board: GOG Foundation, MSD Oncology. J. Srimani: Financial Interests, Personal, Full or part-time Employment: Takeda; Financial Interests, Personal, Stocks/Shares: Takeda, BMRN, PFE, GILD. J. Yin: Financial Interests, Personal, Full or part-time Employment: Takeda; Financial Interests, Personal, Stocks/Shares: Takeda. W.L. Trepicchio: Financial Interests, Personal, Full or part-time Employment: Takeda; Financial Interests, Personal, Stocks/Shares: Takeda; Financial Interests, Personal, Licencing Fees or royalty for IP: Takeda. C. Gorgun: Financial Interests, Personal, Full or part-time Employment: Takeda; Financial Interests, Personal, Stocks/Shares: Takeda. G. Kichenadasse: Financial Interests, Personal, Full or part-time Employment: Southern Oncology Clinical Research Unit; Financial Interests, Personal, Leadership Role: Southern Oncology Clinical Research Unit; Financial Interests, Personal, Research Grant: Aucentra, Henlius, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
97P - Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)
Presenter: Changhoon Yoo
Session: Poster session 17
101P - Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
Presenter: Harpreet Wasan
Session: Poster session 17
102P - Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster session 17
103P - Individual patient data (IPD) meta-analysis of randomised trials to compare efficacy of second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer (BTC)
Presenter: Jaewon Hyung
Session: Poster session 17
104P - Final analysis of the prospective, randomized phase II STAMP trial: Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in node-positive extrahepatic cholangiocarcinoma (CCA)
Presenter: Hyehyun Jeong
Session: Poster session 17
105P - A phase II study of SHR-1316 plus IBI310 in patients with advanced intrahepatic cholangiocarcinoma after failure of first-line therapy
Presenter: Jia Fan
Session: Poster session 17